Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion for the quarter, compared to $1.83 billion a year earlier, according to data from Benzinga Pro.On Oct. 28, On Monday, Merck & Co Inc MRK and Moderna announced the initiation of INTerpath-009, a pi ...

Moderna (MRNA) is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.Estimates for Moderna’s 2024 loss per share have increased from $9.52 to $9.88 in the past 60 days. During the same period, estimates for 2025 loss per share have risen from $7.37 to $8.59. Image Source: Zacks Investment Re ...

Company Performance - Moderna's stock closed at $55.22, reflecting a +0.77% change, outperforming the S&P 500's gain of 0.16% on the same day [1] - Over the past month, Moderna's shares have declined by 18%, which is significantly worse than the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67% [1] Upcoming Earnings - Moderna is set to release its earnings report on November 7, 2024, with projected earnings of -$1.91 per share, indicating a year-over-year decline of 37.41% [2] - The Zacks Consensus Estimate for revenue is $1.25 billion, down 31.71% from the previous year [2] Full-Year Estimates - The full-year Zacks Consensus Estimates for Moderna indicate earnings of -$9.88 per share and revenue of $3.2 billion, representing year-over-year changes of +19.87% for earnings and -53.33% for revenue [3] Analyst Estimates - Recent modifications to analyst estimates for Moderna reflect evolving short-term business trends, with positive revisions seen as a favorable sign for the company's outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Moderna at 3 (Hold) [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have lost significantly in the past couple of years due to declining sales amid low demand for the vaccine. In the past month, MRNA stock fell more than 20% after management provided an update on its business outlook for the next four years. It also announced plans to slash its research and development (R&D) budget during this period. In the past month, the stock has underperformed the industry's 2.3% ...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The mRNA therapeutics market size has grown steadily in recent years. It will grow from $33.5 billion in 2023 to $34.76 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The mRNA therapeutics market size is expected to see steady growth in the next few years. It will grow to $40.69 billion in 2028 at a compound annual growth rate (CAGR) of 4%. During ...

Core Insights - The mRNA cancer vaccines and therapeutics market is projected to grow from $52.85 billion in 2023 to $61.52 billion in 2024, with a compound annual growth rate (CAGR) of 16.4% [2][11] - By 2028, the market size is expected to reach $113.41 billion, reflecting a CAGR of 16.5% [2][11] Market Growth Drivers - Growth in the mRNA cancer vaccines and therapeutics market is driven by factors such as changing lifestyles, increased funding in medical research, favorable regulatory environments, established healthcare infrastructures, and ongoing development of new therapeutic pipelines [3] - Promising clinical trial results, rising awareness of mRNA technology, significant unmet medical needs, and the potential for improved patient outcomes are expected to further fuel market growth [4][5] Market Trends - Anticipated trends include expansion into new therapeutic areas, personalized medicine approaches, advancements in mRNA delivery systems, development of multivalent mRNA vaccines, and integration of artificial intelligence in mRNA design [4] - The increasing prevalence of cancer, influenced by sedentary lifestyles and environmental factors, is expected to drive demand for mRNA cancer vaccines and therapeutics [5] Competitive Landscape - Leading companies in the mRNA cancer vaccines and therapeutics market include Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, and Moderna Therapeutics Inc., among others [6][8] - Companies are focusing on innovative treatments, particularly mRNA cancer vaccines, to meet the rising demand for effective cancer therapies [6] Regional Insights - North America was the largest market for mRNA cancer vaccines and therapeutics in 2023, while Asia Pacific is anticipated to be the fastest-growing region in the forecast period [9]

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), of the important October 8, 2024 lead plaintiff deadline. So what: If you purchased Moderna securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Moderna, Inc. securities between January 18, 2023, and June 25, 2024, of the upcoming lead plaintiff deadline on October 8, 2024, for a class action lawsuit related to misleading statements about the effectiveness of their RSV vaccine [2][5]. Group 1: Class Action Details - Investors who bought Moderna securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 8, 2024 [3]. - The lawsuit alleges that Moderna made false and misleading statements regarding the effectiveness of its mRNA-1345 RSV vaccine, which was claimed to be less effective than represented [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4].

Group 1: Moderna's Norovirus Vaccine Study - Moderna has initiated the phase III Nova 301 study for its mRNA norovirus vaccine candidate, mRNA-1403, with the first participant dosed in the United States [1] - The study aims to enroll approximately 25,000 participants globally, focusing on older adults at higher risk of norovirus infection [2][3] - Norovirus is highly contagious and a leading cause of diarrheal disease, resulting in around 200,000 deaths annually [3] Group 2: Partnership in Taiwan - Moderna has entered a joint agreement with Cenra Healthcare to promote its mRNA respiratory vaccine portfolio in Taiwan, including the COVID-19 vaccine, Spikevax [4] - Moderna will handle the manufacturing and distribution of the vaccines, while Cenra Healthcare will manage promotion and education activities [5] Group 3: Stock Performance and Rankings - Moderna's shares have decreased by 32.8% this year, contrasting with a 1.8% decline in the industry [2] - Currently, Moderna holds a Zacks Rank of 3 (Hold), while other biotech stocks like ANI Pharmaceuticals, Krystal Biotech, and Fulcrum Therapeutics have higher rankings [6]

Core Insights - Klotho Neurosciences, Inc. has announced the addition of Dr. Robert Langer to its Scientific Advisory Board, highlighting his belief in the company's mission and potential in developing therapies for neurodegenerative diseases [1][4] Company Overview - Klotho Neurosciences is focused on innovative therapies for neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's disease, leveraging research on the Klotho protein, which has shown neuroprotective potential in preclinical models [3][5] - The company holds patents for its secreted form of Klotho (s-KL) in the USA, Europe, Hong Kong, and China, indicating a strong intellectual property position [3] Dr. Robert Langer's Role - Dr. Langer is a prominent figure in biotechnology, known for his contributions to drug delivery systems and mRNA-based therapeutics, including the COVID-19 vaccine [2] - His involvement is expected to provide significant guidance on the scientific and clinical development of Klotho Neurosciences' product candidates, marking a milestone for the company [4] Strategic Direction - The company aims to position itself at the forefront of addressing the challenges of treating neurodegenerative diseases, with Dr. Langer's expertise seen as invaluable for advancing its pipeline [4]